drugset / Trial / NCT02821910
Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combinations (FDC) tablets containing empagliflozin, linagliptin \& metformin extended release (XR) and the single tablets of empagliflozin, linagliptin and metformin XR administered simultaneously.
Timeline
- Start
- 2016-07-20
- Primary completion
- 2016-10-01
- Completion
- 2016-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Empagliflozin | Small molecule | — | Oral |
| Subject | Empagliflozin/Linagliptin/Metformin XR | Unknown | — | Oral |
| Subject | Linagliptin | Unknown | — | Oral |
| Subject | Metformin | Small molecule | — | Oral |
Indications
No indication recorded.